Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases... Show more
INSM saw its Momentum Indicator move above the 0 level on May 22, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 103 similar instances where the indicator turned positive. In of the 103 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for INSM just turned positive on May 19, 2025. Looking at past instances where INSM's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
INSM moved above its 50-day moving average on June 02, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INSM crossed bullishly above the 50-day moving average on June 06, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The 50-day moving average for INSM moved above the 200-day moving average on June 20, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INSM advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 166 cases where INSM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
INSM broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: INSM's P/B Ratio (200.000) is slightly higher than the industry average of (16.539). P/E Ratio (0.000) is within average values for comparable stocks, (59.016). INSM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.300). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (47.393) is also within normal values, averaging (255.605).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a biopharmaceutical company
Industry Biotechnology
A.I.dvisor indicates that over the last year, INSM has been closely correlated with THAR. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then THAR could also see price increases.
Ticker / NAME | Correlation To INSM | 1D Price Change % | ||
---|---|---|---|---|
INSM | 100% | -0.54% | ||
THAR - INSM | 74% Closely correlated | +8.02% | ||
AGIO - INSM | 46% Loosely correlated | -2.12% | ||
ROIV - INSM | 45% Loosely correlated | -1.21% | ||
KRYS - INSM | 42% Loosely correlated | -0.81% | ||
IONS - INSM | 42% Loosely correlated | +0.91% | ||
More |